Osteoporosis guidelines.
Laupacis
Andreas
A
D002170:Canada; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D020849:Raloxifene Hydrochloride / Q000191:economics / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000191:economics / Q000627:therapeutic use*
D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride